Key Insights on Gross Profit: Vertex Pharmaceuticals Incorporated vs Dr. Reddy's Laboratories Limited

Pharma Giants' Profit Battle: A Decade in Review

__timestampDr. Reddy's Laboratories LimitedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201475801000000519428000
Thursday, January 1, 201585403000000906794000
Friday, January 1, 2016922810000001491717000
Sunday, January 1, 2017783560000002213533000
Monday, January 1, 2018763040000002638058000
Tuesday, January 1, 2019834300000003615063000
Wednesday, January 1, 2020940090000005469383000
Friday, January 1, 20211030770000006670200000
Saturday, January 1, 20221138400000007850400000
Sunday, January 1, 20232029720000008607000000
Monday, January 1, 20241636070000009489600000
Loading chart...

Cracking the code

A Decade of Gross Profit: Vertex Pharmaceuticals vs. Dr. Reddy's Laboratories

In the competitive landscape of pharmaceuticals, understanding financial performance is crucial. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outperformed Vertex Pharmaceuticals Incorporated in terms of gross profit. From 2014 to 2023, Dr. Reddy's saw a remarkable growth of over 167%, peaking in 2023 with a gross profit more than double its 2014 figure. In contrast, Vertex Pharmaceuticals, while showing steady growth, achieved a gross profit increase of approximately 1,558% over the same period, albeit from a much smaller base.

Key Insights

  • Dr. Reddy's Laboratories: Dominated the decade with a consistent upward trend, reaching its highest gross profit in 2023.
  • Vertex Pharmaceuticals: Despite starting with a lower base, it showed impressive growth, highlighting its potential in the market.

The data for 2024 is incomplete, indicating a need for further analysis to understand future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025